GlassScriptPhysician profile
Natalie June Dean
NPI 1427678994
$2,735.02
in general payments reported to CMS, 2019-2025
26 companies · $2,463 in 2025
The $2,463 reported for 2025 was more than what 95% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $272 · 2025: $2,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686 · Education: $49.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.92 |
| Education | $49.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $361.69 | 2024-2025 | Tysabri, Vumerity, Leqembi |
| Alexion Pharmaceuticals, INC. | $277.73 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $269.57 | 2025 | |
| Argenx US, INC. | $256.84 | 2025 | Vyvgart Hytrulo |
| Amgen INC. | $210.45 | 2025 | Uplizna |
| Genentech USA, INC. | $194.80 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Abbvie INC. | $136.92 | 2025 | |
| Piramal Critical Care | $114.54 | 2024 | |
| Eisai INC. | $104.56 | 2025 | |
| Tg Therapeutics, INC. | $88.30 | 2025 | |
| Ucb, INC. | $86.49 | 2025 | Rystiggo |
| Janssen Biotech, INC. | $79.71 | 2025 | |
| Emd Serono, INC. | $63.91 | 2025 | |
| Tanabe Pharma America, INC. | $59.98 | 2024-2025 | Radicava |
| Harmony Biosciences LLC | $50.55 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $49.73 | 2025 | Acthar |
| Acadia Pharmaceuticals INC | $48.18 | 2025 | Nuplazid |
| Octapharma USA, INC. | $48.13 | 2025 | Octagam Immune Globulin (Human), Panzyga |
| Neurocrine Biosciences, INC. | $43.67 | 2025 | |
| Cycle Pharmaceuticals INC | $36.16 | 2025 | Tascenso Odt, Bafiertam |
| Pfizer INC. | $34.17 | 2025 | |
| Gilead Sciences, INC. | $31.87 | 2024 | |
| Ani Pharmaceuticals, INC. | $25.04 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $23.05 | 2025 | Hyqvia |
| Axsome Therapeutics, INC. | $21.17 | 2025 | Symbravo |
| Neurelis, INC. | $17.81 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.